At Best Startup UK we track over 130,000 UK startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top United Kingdom based COO’ operating in the Biotechnology space. If you think a COO’ is missing from this list, feel free to contact our editor on editor@beststartup.co.uk.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Companies House UK, Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Michael Skynner
Chief Operating Officer of Bicycle Therapeutics
Mike Skynner, Ph.D., is vice president of operations at Bicycle Therapeutics.He joined Bicycle Therapeutics from Pfizer where he led rare disease efforts in Europe and founded and ran the Pfizer Rare Disease Consortium (RDC). The RDC was an innovative agreement between Pfizer and 20 leading U.K. universities that created research partnerships between Pfizer, academic researchers and patient groups to develop new therapies for rare and orphan diseases using a new collaborative paradigm. As part of those activities he also established Pfizer’s Genetic Medicine Institute, a bespoke research unit in central London embedded within the U.K. gene therapy academic community. Previously, he established a discovery performance unit at GlaxoSmithKline (GSK) focused on developing therapeutics targeting inflammatory kinases using an externalised and partnered model with leading European biotechnology companies. In his time at GSK he successfully advanced multiple molecules from screening into clinical trials. Prior to GSK he co-founded a successful biotech start-up company, Cambridge Biotechnology Ltd., (CBT), which specialised in developing small molecule and peptide therapeutics for inflammation and metabolic disease. CBT was sold to Swedish Orphan Biovitrum. Mike obtained his Ph.D. in biochemistry at Imperial College and is an author on over 30 peer-reviewed scientific publications.
Follow Michael Skynner:
About Bicycle Therapeutics: Bicycle Therapeutics is developing a technology for the creation of new generation biotherapeutics.
David Brindley
Chief Operating Officer of Rational Vaccines
David is an international thought-leader in healthcare risk management, with a particular interest in regenerative medicines. His multi-disciplinary research seeks to evaluate and develop systematic, rigorous and transparent risk management tools supporting the translation of life-science innovations into commercially viable products and services.
Follow David Brindley:
About Rational Vaccines: Rational Vaccines is a pre-clinical stage that develops live-attenuated herpes simplex virus vaccines.
Michael Anstey
Co-Founder and Chief Operating Officer of Proteorex Therapeutics Inc.
Michael Anstey is an Investment Director specialising in healthcare investments. Before joining CIC he was a Principal in the Healthcare Practice Area at The Boston Consulting Group’s (BCG) Toronto office. Michael has experience in advising multinational healthcare businesses across North America, Europe, India, and Japan on a broad range of topics, including corporate strategy, sales and marketing, new launches, R&D and medical strategy, and M&A. Michael was co-founder and COO of an early stage biotechnology company focused on developing small molecule drugs that target protein-protein interactions implicated in disease. Prior to BCG, Michael worked in venture capital, where he focused on investing in early stage healthcare and life science businesses. Michael earned his DPhil in Zoology in the field of neurobiology, jointly supervised by professors at the University of Cambridge and the University of Oxford. Michael sits on the board of Bicycle Therapeutics.
Follow Michael Anstey:
About Cambridge Innovation Capital, Proteorex Therapeutics Inc.: Expanding horizons to find cures
Sebastian Brunemeier
Founder & COO of Samsara Therapeutics
Sebastian Brunemeier is the Founder and COO of Samsara Therapeutics.
Follow Sebastian Brunemeier:
About Cyclone Therapeutics, Samsara Therapeutics, U.S. Department of State, University of Oxford: Samsara Therapeutics is a biopharmaceutical company that aims to discover therapeutics to treat rare genetic and neurodegenerative disease.
Andrew Webster
COO of Polymateria
Andrew Webster is the Chief Operating Officer of Polymateria.
Follow Andrew Webster:
About Polymateria: Polymateria is a London-based startup advancing science to help nature deal with plastic pollution.
Ivan Griffin
COO & Co-Founder of BenevolentAI
Ivan joined NESTA in March 2009. He makes and manages investments in the Healthcare sector. Prior to joining NESTA Ivan spent four years at IP Group where he was predominantly focused on healthcare and life science businesses. At IP Group his role encompassed all aspects of technology commercialisation, including identification of investment opportunities, spin-out company formation, business and corporate development as well as private and public equity financings and trade sales. Before joining IP Group Ivan spent two years at Oxford Technology Venture Capital Trust, and a year in post-doctoral research where he published several scientific papers.
Follow Ivan Griffin:
About BenevolentAI: BenevolentAI is a developer of artificial intelligence and computational medicine technologies.
Claire Woodthorpe
VP Europe and COO of Lightpoint Medical
Claire Woodthorpe is the VP Europe and COO at Lightpoint Medical.
Follow Claire Woodthorpe:
About Lightpoint Medical: Lightpoint Medical, a medical device company, develops intra-operative imaging technology that can detect cancer during surgery.
Sherden Timmins
Co-founder & Chief Operating Officer of Camallergy
Sherden led the formation of Camallergy and spin-out from Cambridge University Hospitals following his MBA at the Cambridge Judge Business School. He designed the Cambridge Peanut Allergy Clinic, and led start-up funding rounds and early drug development in preparation for clinical trials. An engineering graduate from Imperial College London and a former management consultant at top-tier firms Booz & Co. (now Strategy&) and Accenture, Sherden has experience across a range of industries in strategy and managing complex and technical programmes.
Follow Sherden Timmins:
About Camallergy: Camallergy develops and provides new treatments for common food allergies.
Mike Birch
Chief Operating Officer of F2G
Follow Mike Birch:
About F2G: F2G discovers and develops novel drugs for the treatment of life-threatening fungal diseases.
Priya Mande
Chief Operating Officer of Psioxus Therapeutics
Priya Mande has over 20 years of experience in the pharmaceutical and biotech sector. She was previously at PowderMed responsible for vaccine immunotherapeutic projects, collaboration with academic institutions and Joint Ventures with other Pharma companies targeting influenza, chronic viral diseases and cancer. Priya was also the Vaccine Research Project Leader for Influenza at Pfizer before becoming COO of Hybrid BioSystems in 2009. She has previously held various roles within Glaxo Wellcome and Glaxo SmithKline over a 12 year period where she was most recently senior Director of R&D Business Projects. Priya studied Biochemistry at Brunel University, received a MBA with distinction from the London Business School and has a Diploma in Company Direction from the Institute of Directors. Priya has received several awards for project leadership including an international collaboration award at the 26th US Army Science Conference.
Follow Priya Mande:
About Psioxus Therapeutics: Psioxus Therapeutics is a cancer gene therapy company delivers medicines of value to patients with cancer.
Nick Lench
Chief Operating Officer & Chief Scientific Officer of Congenica
Nick was previously Director of the NE Thames Regional Genetics Service at Great Ormond Street Hospital for Children, London, with responsibility for the strategic and operational management of a genetics service that provides DNA diagnostic testing to a population of approximately 4.5M people. Nick is an honorary Reader at the UCL Institute of Child Health, London and has over 25 years of research experience in human molecular genetics and was awarded a personal chair in Medical Genetics at Cardiff University in 2005. As founding CEO of London Genetics Ltd and Programme Director at Oxagen Ltd, Nick has gained significant expertise in establishing and managing academic, healthcare and commercial partnerships in biomedical discovery and diagnostics.
Follow Nick Lench:
About Congenica: Congenica is a biotechnology company that provides a diagnostic decision support platform.
Samantha Vieira
Chief Operating Officer of Anjarium Biosciences
Samantha Vieira is the Chief Operating Officer at Anjarium Biosciences.
Follow Samantha Vieira:
About Anjarium Biosciences: Anjarium is focused on creating new class of non-viral gene therapies to deliver predictable ,inclusionary ways to tackle genetic diseases.
Christopher Vann
Senior Vice President, Chief Operating Officer of Autolus
Christopher Vann leads commercial activities for Autolus. An industry veteran with 30 years’ experience in both development and business roles, he joined Autolus from Hoffmann-La Roche’s Swiss headquarters, where he was latterly responsible for leading the lung cancer commercial team and general management of the Tarceva brand. He has extensive experience of global lifecycle management of oncology products as well as implementing marketing strategy at a regional and national level. This includes launching several oncology, immunology and transplant products in countries such as China, Japan, Romania, Russia, South Africa, the UK and the USA. He gained his degree in toxicology and pharmacology from the School of Pharmacy, University of London.
Follow Christopher Vann:
About Autolus: Autolus is in T-cell programming and manufacturing technology.
Thomas Fleming
Co-Founder & COO of Arctoris
Thomas Fleming is an award-winning chemist, cancer researcher, and SME Leader of the Royal Academy of Engineering. Tom is the Co-Founder & COO at Arctoris.
Follow Thomas Fleming:
About Arctoris: Arctoris is a tech-enabled platform company in biotechnology, combining robotics & data science to accelerate drug discovery.
Chris Townsend
Chief Operating Officer of CellNovo
Chris has over 25 years of experience in medtech, in particular the transfer of devices from R&D in production and their subsequent scale to large volume manufacture. He has worked at Owen Mumford (Auto injectors), Microvisk (Sensors), Sphere Medical (Biosensors) and Innovata (Inhalers) where he held senior management team roles.
Follow Chris Townsend:
About CellNovo: CellNovo is a medical device company developing a wireless therapeutic system for diabetic patients.
Victor Dillard
Founder , COO & CEO of Desktop Genetics
A former chemical engineer keen on seeing personalized treatment realized, Victor has spent the past three years leading Desktop Genetics’ business development and CRISPR genome-editing initiatives. He has closed several partnerships with leading life science companies, placing Desktop Genetics at the forefront of CRISPR therapeutics research. Informed by his previous experience at P&G, GlaxoSmithKline, Flagship Ventures, Victor believes that software will be the key to unlocking the full potential of biotech R&D. He holds MEng, Chemical Engineering from Imperial College London and an MPhil in Bioscience Enterprise from the University of Cambridge.
Follow Victor Dillard:
About Desktop Genetics: Desktop Genetics is an international company to help researchers discover and treat the root genetic causes of human disease.
Sacha Carton
Co-Founder & COO of Airfinity
Sacha is co-founder & COO at Airfinity – a science information and analytics company. He is a data, tech and media entrepreneur who previously co-founded ad pepper media (FRA: APM), Adbrain (sold to NSDQ: TTD), Scala Ventures and advisory firm Ogmenta and has been an investor, advisor and director in multiple media, data, adtech, PE and M&A companies in Europe and the US.
Follow Sacha Carton:
About Airfinity, Scala Ventures: Airfinity is a science information and analytics company
Katherine Willetts
COO of DynamX Medical
After graduating from the University of Warwick in 2011 with a BSc. in Biochemistry Katie became interested in translational medicine and biophysics. She went on to complete her PhD at UCL in 2015 in the technical development of infrared spectroscopy for biomedical applications. She has published several papers relating to the handling and analysis of biological samples in infrared spectroscopy research. Several aspects of her research have proven key in the development of the BeamLine algorithm. Katie co-founded BeamLine Diagnostics in March 2015 and continues to work on technical development and data analysis.
Follow Katherine Willetts:
About DynamX Medical, Oxford Pharmagenesis: DynamX Medical has developed a diagnostic system for cancer and pre-cancer.
Nick Denison-Pender
COO of Prescient Healthcare Group
Nick, is COO joined Prescient in 2010. After studying engineering, he held various positions focused on business improvement, mainly in the construction industry. He has worked in many parts of the world, establishing and embedding businesses into local markets. At Prescient, he holds overall responsibility for their operations and infrastructure and has been instrumental in setting up the departments, processes and procedures required to support a growing business.
Follow Nick Denison-Pender:
About Prescient Healthcare Group: Prescient Healthcare Group was founded in London in 1995, originally specializing in competitive insights.
Fiona du Monceau
COO of ExeVir Bio
Fiona du Monceau is the Chief Operating Officer of ExeVir Bio.
Follow Fiona du Monceau:
About ExeVir Bio: ExeVir Bio is a Belgium-based company that develops single-domain antibody-based therapies that help patients ward off viral infections.
Liz Littlewood
Chief Operating Officer of Ixchelsis
Liz graduated in Applied Biological Sciences from Sheffield Hallam University in 1995. In 1996 Liz joined the Pfizer Animal Health Group in Sandwich as a team leader in in vitro pharmacology, working across multiple therapeutic areas. Liz held positions of increasing responsibility over the subsequent 11 years, as Project Leader, Head of In vitro Sciences and Lead Discovery. Liz contributed to scientific and business strategy as a member of the Discovery Management Committee and played a major role in the PAH academic and industry strategic alliances. Liz then took up a role as Research Program Manager within Pfizer R&D at Sandwich with responsibility for the planning and operational progression and budgetary management of all R&D projects within the Pain portfolio; from idea through to Proof-of-Concept. Latterly, Liz was appointed as Scientific Development Officer, with a diverse remit, working with the Chief Scientific Officers and Head of the Sandwich site to align the financial and scientific needs of the organization and shape the R&D portfolio at Sandwich. Liz has 18 years leadership experience in the Pharmaceutical Industry. Since 2011 Liz has been Founder and Chief Operating Officer of Ixchelsis Limited.
Follow Liz Littlewood:
About 272BIO, Ixchelsis: Ixchelsis develops an oxytocin receptor antagonist for the treatment of premature ejaculation.
Mike Trower
Founder, Chief Scientific Officer & Chief Operating Officer of NeRRe Therapeutics
Mike is Co-founder and Chief Scientific Officer of KaNDy Therapeutics. It was Mike’s advocacy of the dual mechanism neurokinin-1,3 receptor antagonism, offered by NT-814, to present a novel and potentially transformational non-hormonal therapy for treatment of symptoms of the menopause and other related Women’s Health conditions which led to NT-814 being spun out of NeRRe Therapeutics to create KaNDy Therapeutics in 2017. Mike has broad knowledge of neurokinin receptor biology and, in particular, the emerging science that has established the pivotal role these systems play in neuroendocrinology and female sex-hormone related disorders. Mike is also Co-founder and CSO of NeRRe Therapeutics whose focus is on developing the neurokinin-1 receptor antagonist orvepitant to treat neuronal hypersensitivity disorders including chronic refractory cough. Prior to founding NeRRe, Mike worked in pharmaceutical industry R&D at GSK for nearly 20 years, where latterly he was VP & Head of the External Drug Discovery Group in the Neurosciences Centre for Excellence for Drug Discovery (CEDD). In this position, Mike successfully implemented the CEDD externalisation strategy and advanced a portfolio of preclinical and clinical pipeline assets. Mike has BSc (Hons) and PhD degrees in biological sciences and has held post-doctoral positions at DuPont Inc in Delaware, US, and at the Medical Research Council in Cambridge, UK, under the Nobel laureate Professor Sydney Brenner.
Follow Mike Trower:
About NeRRe Therapeutics: NeRRe Therapeutics is a biotechnology company that develops clinical and pre-clinical neurokinin receptor antagonists.
Cliff Holloway
COO of Benitec Ltd
Cliff brings over 25 years of life science industry experience to Scancell in the development and commercialisation of emerging technologies and therapeutic products including licensing, M&A, corporate financing and operations management. Most recently he was Chief Business and Operating Officer of Benitec Biopharma Ltd (ASX:BLT, NASDAQ:BNTC). Prior to his role at Benitec he held the position of Managing Director at Sienna Cancer Diagnostics Ltd (ASX:SDX), and also for therapeutic antibody development companies Immune System Therapeutics Ltd and Biosceptre International Ltd. He was formerly VP of Business Development at Arana Therapeutics Ltd, which was acquired by US-based Cephalon Inc (now Teva) in 2009, and he is currently a director of investment fund Newstar Ventures Pty Ltd. Cliff holds a Bachelor of Pharmacy and a PhD in Medicinal Chemistry from the University of Nottingham.
Follow Cliff Holloway:
About Benitec Ltd, Newstar Ventures Pty Ltd., Scancell: Benitec Biopharma is using patented ‘gene-silencing’ technology to develop drugs for chronic and life-threatening human diseases.
Daniel Green
Chief Operating Officer of Caristo Diagnostics
Experienced start-up executive, most recently COO at Perspectum Diagnostics. Led multiple products through successful FDA and CE clearances. 20 years in medical device industry, both hardware and software.
Follow Daniel Green:
About Caristo Diagnostics: Caristo Diagnostics utilises standard CT scans to identify potentially heart-stopping plaques
Neville Hamlin
Financial Director and Chief Operating Officer of Centre for Process Innovation
Neville holds board directorships and company secretary positions for the CPI group of companies. A professional qualified chartered accountant with an MBA, he has over 25 years experience in the semiconductor and hi-tech industry with over 20 years in senior management and board positions. Neville has established key start-up companies in the North East of England: he set up the Siemens Microelectronics facility in 1995, moving from Siemens HQ in Germany to do so, and he established Atmel’s manufacturing site in the UK in 2000; he has taken a biofuel company to AIM listing and has also been involved in several MBOs/MBIs. He established a Nanotechnology Centre of Excellence (Cenamps) in 2003 and was instrumental in obtaining the funding to establish CPI’s Printable Electronics Centre at NETPark and was responsible for the design and building programme. Neville possesses a broad knowledge of business start-up and development, financial engineering, multi-national trading structures, and public vs. private sector drivers. He joined the newly merged CPI organisation from Cenamps in April 2008 as Finance Director and Chief Operating Officer.
Follow Neville Hamlin:
About Centre for Process Innovation: The CPI is a technology innovation center helps its clients develop, prove, prototype, and commercialize products and processes.
Paul Gemmill
Chief Operating Officer of Biotechnology and Biological Sciences Research Council
Paul studied modern history at Oxford before gaining an MBA from London Business School. Before joining BBSRC he was Director of Regulation at the Human Fertilisation and Embryology Authority, and in 2000 he was a founding director of the Disability Rights Commission. Paul also has considerable experience in the voluntary sector including strategic fundraising with The Prince’s Trust and leading strategy for the British Red Cross Society. Prior to that Paul worked in the private sector for National Power PLC. Paul is a Fellow of the Royal Society of Biology.
Follow Paul Gemmill:
About Biotechnology and Biological Sciences Research Council: BBSRC invests in bioscience research and training focused on climate change, sustainable food production, land use and energy production.
Minaam Abbas
Chief Operating Officer of angioClast
Follow Minaam Abbas:
About angioClast: angioClast is a Cambridge biotech startup comitted to transform cancer research.
Ian Abercrombie
Business Unit Director & Chief Operating Officer of NuCana BioMed
Ian Abercrombie has over 25 years experience in the biopharmaceutical and healthcare industry. Ian’s specific expertise includes the clinical development and commercialisation of anti-cancer medicines and companion diagnostics to enable therapies to be targeted to specific patient populations. Ian has wide biopharmaceutical and healthcare experience having initially served in the public health sector before working for Janssen Cilag, Ortho-Biotech, Bioenvision and Caris Life Sciences. Whilst at Bioenvision, Ian played a major role in developing and commercialising clofarabine, the first new drug to be approved specifically for childhood acute leukaemia in Europe for over thirty years.
Follow Ian Abercrombie:
About Medannex Ltd, NuCana BioMed: NuCana BioMed, a biopharmaceutical company, develops and commercializes rationally designed medicines for significant unmet medical needs.
Angela Scott
Chief Operating Officer & Founder of TC BioPharm
Angela Scott is the Founder and Chief Operating Officer at TC BioPharm.
Follow Angela Scott:
About MIT Global Entrepreneurship Bootcamp, TC BioPharm: TC BioPharm developing safer, cheaper, consistent and durable CAR-T drugs for hematological and solid tumors.
Cameron Shaw
Founder and COO of Virax Biolabs
Cameron Shaw is the founder and Chief Operations Officer at Virax Biolabs.
Follow Cameron Shaw:
About Virax Biolabs: Virax Biolabs is an innovative Biotechnology company focused on the prevention, detection and diagnosis of viral diseases
Jaymin Amin
COO of Ingenza
Jaymin Amin has a successful track record of 15 years of sales, marketing and financial experience in life sciences start-up companies. Working in the life sciences publishing division of the Daily Mail group, Jaymin delivered record revenues and profits, before leaving to co-found a life sciences media company of his own. He joined the board of Ingenza in 2006 as financial director. After helping to grow the business four fold in his first four years, Jaymin was promoted to chief operating officer in 2011.
Follow Jaymin Amin:
About Ingenza, ProFactor Pharma: Ingenza is an industrial biotechnology company.
Derek Lindsay
Chief Operating Officer of AMR Centre
Derek was a co-founder of Redx Pharma and its Chief Operating Officer from 2012-17. His former roles include being a Director of Innovation of pharmaceutical industry consortium Britest Ltd from 2006 to 2012, and R&D Director of Avecia Pharmaceutical Products in a management career of more than 20 years. Derek has worked in R&D, Process Development and Hazards at Avecia and its predecessor businesses, Zeneca and ICI, which he joined in 1988, after initially working in R&D at BP from 1985.
Follow Derek Lindsay:
About AMR Centre: AMR Centre is a joint private-public initiative to support/accelerate the development of new antibiotics and diagnostics.
Steven Wort
Chief Operating Officer of Elekta
Follow Steven Wort:
About Elekta, Elekta: Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders.
Jamie Ferguson
Chief Operating Officer of ADC Biotechnology
Jamie Ferguson currently serves ADC Biotechnology as chief operating officer. Jamie has more than 30 years of commercial experience, developing, managing and delivering strategies for growth in the contract manufacture of agrochemical, pharmaceutical, and specialty chemical products.
Follow Jamie Ferguson:
About ADC Biotechnology: ADC BIO is an innovative biotechnology company. Specialising in Antibody Drug Conjugates.
David Lane
COO and Co-Founder of EProfiler Solutions
Follow David Lane:
About EProfiler Solutions: EProfiler Solutions develops technology solutions to diagnose diseases.
David Freedman
COO and President of Nanoview Biosciences
Follow David Freedman:
About Nanoview Biosciences: Nanoview Biosciences is developing proprietary products that support research, translation and delivery of precision medicine.
Simon Tyler
Chief Operating Officer of CatSci
Simon obtained an MA in Natural Sciences (Chemistry) from Hertford College, Oxford in 1995 and earned a PhD in 1998 after research on asymmetric synthesis in the group of Prof. Laurence M. Harwood. Then followed a two-year post-doctoral stint with Prof. Barry M. Trost at Stanford University, studying the catalysis of the Claisen rearrangement. In 2001, Simon returned to the UK to join Process R&D in AstraZeneca, gaining experience and understanding of the multi-disciplinary needs of drug development to lead significant process development projects ranging from candidate selection to Phase III, therein establishing a record of exploiting innovative synthetic and catalytic chemistry for the manufacture of drug candidates. After ten years in big pharma, Simon played a pivotal role as a co-founder of CatSci Ltd, negotiating the financial terms for the asset transfer and service agreement with AstraZeneca. After an initial operational role during the establishment of the new start-up, he subsequently took on commercial responsibility for the company, overseeing growth to a multi-million pound business. He currently serves as Chief Operating Officer, focused on unleashing the talents of staff across the organisation to exceed the expectations of customers. As a dynamic leader, he is committed to the development of others through vision, participation and affiliation.
Follow Simon Tyler:
About CatSci: CatSci provides innovative process research and development services to emerging, mid-sized and large pharma.
Peter Bryant
COO of FarmaTrust
Peter Bryant the Chief Operating Officer of FarmaTrust. This is a new company which uses modern technologies such as blockchain, artificial intelligence and big data analytics to prevent counterfeit drugs from contaminating the supply chain. This gives customers and patients the security that the medicines they are purchasing are genuine. The FarmaTrust system also creates efficiencies for Pharmaceutical companies and also regulatory compliance. Peter Bryant also works in numerous positions supporting companies and startups, he is the Chairman of Imployable, an app startup looking to disrupt the recruitment and education sectors.
Follow Peter Bryant:
About FarmaTrust: FarmaTrust is the most efficient global tracking system which provides security to both patients and the pharmaceutical industry.
Sean Pollock
Founder & COO of Opus Medical
Doctor Sean Pollock researched and developed the Breathe Well technology over 5 years for his Masters and PhD in medical physics, transitioning into a full time role in the company after the completion of his PhD.
Follow Sean Pollock:
About Opus Medical: Opus Medical designs and manufactures medical devices for use in motion management during cancer treatment.
John Whittaker
Chief Operating Officer of Celleron Therapeutics
Follow John Whittaker:
About Celleron Therapeutics: Celleron Therapeutics is an oncology company dedicated to funding new and innovative treatments for cancer.
